BMY Q4 2018 Earnings — Bristol-Myers Squibb Company Revenue & Financial Results | Market Cap Arena

BMYBristol-Myers Squibb Company

$121B

Q4 2018 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$6.0B+9.6% YoY

Gross Profit

$4.3B71.7% margin

Operating Income

$1.6B26.6% margin

Net Income

$1.2B19.4% margin

EPS (Diluted)

$0.73

QoQ Revenue Growth

+5.0%

Cash Flow

Operating Cash Flow

$2.4B

Free Cash Flow

$2.1B

Stock-Based Comp.

$53M

Balance Sheet

Total Assets

$35.0B

Total Liabilities

$20.9B

Stockholders' Equity

$14.0B

Cash & Equivalents

$6.9B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6.0B	$5.4B	+9.6%
Gross Profit	$4.3B	$3.8B	+14.1%
Operating Income	$1.6B	$1.0B	+54.5%
Net Income	$1.2B	-$2.3B	+149.8%

Revenue Segments

Opdivo

$1.8B32%

Eliquis

$1.7B31%

Orencia

$731M13%

Sprycel

$536M10%

Yervoy

$384M7%

Baraclude

$165M3%

Reyataz

$99M2%

Empliciti

$69M1%

Sustiva Franchise

$54M1%

Hepatitis C Portfolio

$4M0%

Geographic Segments

UNITED STATES

$3.3B56%

Europe

$1.5B25%

Rest Of World

$1.0B17%

Other Region

$146M2%